ADA Updates Standards of Care to Include Teplizumab for Delaying T1D, Reflect Emphasis on NAFLD
At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.
Source: hcplive.com
